Curated News: Medical Meetings

• share
• favorite_border

Os investigadores da Mayo Clinic constataram que um medicamento oral, apixabana, utilizado para tratar a formação de coágulos de sangue em pacientes submetidos a terapia contra o câncer, é seguro e eficaz. O medicamento foi associado a uma menor quantidade de complicações hemorrágicas e menos formação recorrente de coágulos sanguíneos, em comparação com a heparina de baixo peso molecular. Os resultados foram apresentadas na assembleia anual da Sociedade Americana de Hematologia por Robert McBane II M.D., um cardiologista da Mayo Clinic.

• share
• favorite_border

Investigadores da Mayo Clinic desenvolveram duas novas estratégias que podem melhorar o desempenho da terapia do receptor de antígeno quimérico (terapia com células T CAR) no tratamento do câncer. Eles apresentarão os resultados de suas pesquisas pré-clínicas na assembleia anual de 2018 da Sociedade Americana de Hematologia em San Diego, EUA.

• share
• favorite_border

The Health Effects Institute (HEI) convened an Energy Research Committee to help ensure the protection of public health during such development. A symposium at the 2018 Society for Risk Analysis (SRA) Annual Meeting will summarize the Committee’s review approach and preliminary findings and provide initial options for future research intended to fill knowledge gaps.

• share
• favorite_border

The symposium presentation at the Society for Risk Analysis (SRA) Annual Meeting will review current topics in occupational risk analysis that health officials are currently challenged with, including chronic traumatic encephalopathy (CTE) in football and exposure to metals via dermal contact in the workplace.

• share
• favorite_border

Los científicos de Mayo Clinic desarrollaron dos estrategias nuevas que podrían mejorar el rendimiento de la terapia de células T con receptor de antígeno quimérico en el tratamiento del cáncer.

• share
• favorite_border

Many of the substances that humans consume on a regular basis as parts of their basic diet actually contain harmful toxins. Rice, barbecued meat and drinking water all pose threats to human health as hosts to potent toxins, carcinogens and opportunistic pathogens. In many cases, the rise in concentrations of these harmful substances is a direct result of human activity, such as the use of harmful pesticides in crops and even advances in green technology.

• share
• favorite_border

Precision medicine will extend beyond prediction, diagnosis and treatment of disease to also include broader health initiatives, including prevention, nutrition and wellness. These new procedures raise novel legal, policy and ethical issues.

• share
• favorite_border

Los científicos de Mayo Clinic descubrieron que un fármaco oral, el apixabán que sirve para tratar coágulos sanguíneos en los pacientes que reciben terapia oncológica, es seguro y eficaz.

• share
• favorite_border

In a new study published in the Journal of Clinical Oncology, Manuel Hidalgo, MD, PhD, and colleagues conducted a phase I/II trial designed to evaluate the efficacy and safety of nab-paclitaxel given in combination with gemcitabine in patients with pancreatic cancer and reduced health status. The team – based at the Centro Nacional de Investigaciones Oncologicas (Spanish National Cancer Center), where Hidalgo previously served as Director of the Clinical Research Program and Vice Director of Translational Research – reported that the combination of therapies significantly improved survival even in less robust patients with metastatic pancreatic ductal adenocarcinoma (PDAC) compared to gemcitabine alone.

• share
• favorite_border

Perosphere Pharmaceuticals Inc. today announced the presentation of clinical study results demonstrating, "Ciraparantag Safely and Effectively Reverses Apixaban and Rivaroxaban in Age-matched Healthy Volunteers as Measured by Whole Blood Clotting Time," at the American Society of Hematology (ASH) annual meeting in San Diego on Monday, December 3, 2018.

• share
• favorite_border

After over a decade of preclinical research and development, a new gene therapy treatment for Sickle Cell Anemia (SCA) is reversing disease symptoms in two adults and showing early potential for transportability to resource-challenged parts of the world where SCA is most common.

• share
• favorite_border

SAN DIEGO — Mayo Clinic researchers have developed two new strategies that may improve the performance of chimeric antigen receptor therapy (CAR-T cell therapy) in treating cancer. They are presenting results of their preclinical research at the 2018 annual meeting of the American Society of Hematology in San Diego.

• share
• favorite_border

Dana-Farber Cancer Institute scientists will present research marking significant advances against the hematologic cancer multiple myeloma at the ASH Annual Meeting.

• share
• favorite_border

Members of the medical community are concerned with how they can make facts ‘attractive’ again and how trust in scientific information can be rebuilt, moving society towards a “post-trust” era. The Vaccine Communication symposia presented at the 2018 Society for Risk Analysis (SRA) Annual Meeting, co-organized by the Vienna Vaccine Safety Initiative, will explore concrete ways to improve vaccination policy moving forward in this “post-truth” era.

• share
• favorite_border

A new combination of three drugs that harness the body’s immune system is safe and effective, destroying most cancer cells in 95 percent of patients with recurrent Hodgkin lymphoma, according to the results of an early-phase study.

• share
• favorite_border

SAN DIEGO — Mayo Clinic researchers have found that an oral drug, apixaban, used to treat blood clots in patients undergoing cancer therapy, is safe and effective. The drug was associated with fewer major bleeding events and fewer recurrent blood clots, compared to low-molecular- weight heparin. Their findings were presented at the annual meeting of the American Society of Hematology by Robert McBane II M.D., a Mayo Clinic cardiologist.

• share
• favorite_border

Researchers at Memorial Sloan Kettering Cancer Center (MSK) reported results from a new study that looks at the likelihood of complications for people undergoing bone marrow transplants (BMTs). The observational study found that people with lower gut microbiota diversity before having a transplant appear to be at higher risk for developing complications. These findings further support evidence that the connection between microbiota and outcomes starts before people begin the transplantation process. These findings were presented as part of the 2018 annual meeting of the American Society of Hematology (ASH) press program.

• share
• favorite_border

The American Society for Radiation Oncology (ASTRO) recently named three leaders in radiation oncology as the recipients of its Gold Medal award. Patricia Eifel, MD, FASTRO, David Jaffray, PhD, and Ralph Weichselbaum, MD, were awarded the highest honor bestowed upon ASTRO members and recognized for their achievements at ASTRO’s 60th Annual Meeting in San Antonio.

• share
• favorite_border

New results from clinical trials of immunotherapy and experimental targeted agents for patients with leukemia and lymphoma are being presented by Dana-Farber Cancer Institute researchers at the ASH Annual Meeting.

• share
• favorite_border

A follow-up analysis of patients enrolled in a Phase I/II multi-center trial for diffuse large B-cell lymphoma (DLBCL) reported 51 percent of patients receiving an anti-CD19 chimeric antigen receptor (CAR T) called axi-cel were still alive two years post-treatment. The study, co-led by Sattva Neelapu, M.D., professor of Lymphoma & Myeloma at The University of Texas MD Anderson Cancer Center, reported its findings in the Dec. 2 online issue of The Lancet Oncology and during a presentation at the 60th American Society of Hematology Annual Meeting & Exposition in San Diego.

• share
• favorite_border

New drugs that harness the body’s immune system to destroy cancer cells appear to increase the effectiveness of later drug therapies for non-Hodgkin and Hodgkin lymphoma patients, new research suggests. This happens, scientists say, even for repeat drug therapies whose initial attempts failed to stop or reverse the disease.

• share
• favorite_border

Moffitt Cancer Center partnered with 16 academic cancer centers to analyze real world data of 274 patients treated commercially with Yescarta® (axicabtagene ciloleucel), one of two CAR T products that is now standard of care for patients with diffuse large B cell lymphoma (DLBCL) who have not responded to two or more therapies. The researchers then compared those figures with results from the pivotal ZUMA-1 trial, which included 101 patients.

• share
• favorite_border

Systems biology analyses by Rutgers Cancer Institute of New Jersey researchers examining drug resistance to a common antibody therapy for non-Hodgkin lymphoma suggest calcium signaling may have an influence in addressing this treatment obstacle.

• share
• favorite_border

An investigational immunotherapy drug has demonstrated efficacy and an acceptable safety profile in the treatment of follicular lymphoma, diffuse large B-cell lymphoma and other B cell non-Hodgkin lymphoma subtypes. The lead investigator from Rutgers Cancer Institute of New Jersey shares more on the phase 1 trial.

• share
• favorite_border

An international phase-2 trial of a CAR-T cell therapy—to be published on-line Dec. 1 in the New England Journal of Medicine (and presented at the ASH annual meeting in San Diego)—found that 52% of patients responded favorably to the therapy; 40% had a complete response and 12% had a partial response. One year later, 65% of those patients were relapse-free, including 79% of complete responders. The median progression-free survival “has not been reached.”

• share
• favorite_border

A new study led by researchers at Beth Israel Deaconess Medical Center (BIDMC) investigated rates of bloodstream infection among patients with or without catheters in outpatient hemodialysis facilities in New England.

• share
• favorite_border

CHICAGO - MRI scans show that repetitive blows to the head result in brain changes among youth football players, according to a new study being presented today at the annual meeting of the Radiological Society of North America (RSNA).

• share
• favorite_border

The latest results from an ongoing clinical study incorporating the immunotherapy SurVaxM as part of combination treatment for glioblastoma show that this investigational drug is safe, well-tolerated and extended survival even among the hardest-to-treat subgroups of patients. The findings were presented at the Society for Neuro-Oncology Annual Meeting in New Orleans.

• share
• favorite_border

The American Society for Cell Biology is pleased to announce the 2018 Women in Cell Biology career awards. Winners will be acknowledged during the ASCB|EMBO Meeting in San Diego in December.

• share
• favorite_border

The 2018 recipient of the E.E. Just Award is Guillermina (Gigi) Lozano, professor and chair of the Department of Genetics, Division of Basic Science Research at the University of Texas MD Anderson Cancer Center in Houston. Lozano will present the E.E. Just Award Lecture on Sunday, December 9, at 11:00 am at the 2018 ASCB|EMBO Meeting.

• share
• favorite_border

Ahna R. Skop, professor of Genetics at the University of Wisconsin, Madison (UW-Madison), has been chosen as the inaugural recipient of the ASCB Prize for Excellence in Inclusivity. Skop will receive a cash award of $5,000 that she can use to advance inclusion activities at her institution. She will be featured in a video at the 2018 ASCB|EMBO Meeting Keynote Address.

• share
• favorite_border

ASCB has named the winners of the inaugural Porter Prizes for Research Excellence. The $4,000 prize for outstanding postdoctoral research will go to Melanie White, a research fellow at Institute of Molecular & Cell Biology (IMCB) A*STAR, Singapore. A $2,000 award for outstanding predoctoral research goes to Andrew Moore of the University of Pennsylvania (UPenn). White and Moore were chosen because they exemplify the pioneering spirit and contributions to cell biology of one of ASCB’s founders, Keith R. Porter.

• share
• favorite_border

Experts will meet to discuss the latest discoveries in drugs and how best to use existing ones as effectively and safely as possible, at an international conference in Adelaide this week (27-30 November).

• share
• favorite_border

Fred Hutchinson Cancer Research Center’s latest findings on cancer immunotherapies, CRISPR for blood disorders, stem cell transplantation and insights on the immune system and cancer will be featured at the 60th annual meeting of the American Society of Hematology, which will be held Dec. 1–4 in San Diego.

• share
• favorite_border

Penn researchers will present findings at the 60th American Society of Hematology Annual Meeting and Exposition in San Diego, including studies that evaluate CAR T combinations, how the timing of CAR T therapy may impact its effectiveness, and which patients who currently aren’t eligible for CAR T therapy should have greater access.

• share
• favorite_border

The American College of Rheumatology (ACR) welcomes members of the press to write about rheumatology research presented the Winter Rheumatology Symposium in Snowmass Village, CO on January 26 to February 1, 2019.

• share
• favorite_border

Researchers are exploring how irregular filling mechanics may contribute to defects in developing fetal hearts because inefficient filling leads to energy losses that alter the heart’s structure and performance, and studying how filling mechanics and flow structure change over the course of gestation. During the American Physical Society’s Division of Fluid Dynamics 71st Annual Meeting, Nov. 18-20, they will discuss the team’s findings on human fetal cardiac flow measurements collected from normal and abnormal fetal echocardiogram exams.

• share
• favorite_border

Doctors may one day be able to gauge a patient's risk of dementia with an MRI scan, according to a new study from Washington University School of Medicine in St. Louis and the University of California San Francisco. Using a new technique for analyzing MRI data, researchers were able to predict who would experience cognitive decline with 89 percent accuracy.

• share
• favorite_border

Henry Ford Hospital researchers may have unknowingly happened on a new predictor of type 2 diabetes as part of a new ultrasound shoulder study. The predictor may be an ultrasound of the deltoid muscle, which researchers found appears much brighter on diabetic patients than on obese nondiabetic patients.

• share
• favorite_border

New ACAAI President and President-Elect take office

• share
• favorite_border

Urinating into a cup may be a medical necessity at times, but it's often uncomfortable, embarrassing and messy -- especially for women. But what if there were a way to comfortably provide a sample without the splashback? Researchers have created a set of experiments using an anatomically correct female urethra that produced a jet of water with a pressure and flow equivalent to a human bladder. During the APS Division of Fluid Dynamics 71st Annual Meeting, Nov. 18-20, they’ll describe the findings and potential implications.

• share
• favorite_border

Final research results for a new treatment for protection against accidental exposure to peanut were presented today at the American College of Allergy, Asthma and Immunology (ACAAI) Annual Scientific Meeting and published in the New England Journal of Medicine.

• share
• favorite_border

Many parents probably think nothing of sucking on their baby’s pacifier to clean it after it falls to the ground. Turns out, doing so may benefit their child’s health. A Henry Ford Health System study found that babies whose parents sucked on their pacifier to clean it had a lower level of the antibody that is linked to the development of allergies and asthma.

• share
• favorite_border

New research suggests a link between parental sucking on a pacifier and a lower allergic response among young children.

• share
• favorite_border

New research found that over two percent of all U.S. children under the age of 5 have a milk allergy, and 53 percent of food-allergic infants under age 1 have a cow’s milk allergy.

• share
• favorite_border

New research shows it’s possible for both children and adults with uncontrolled asthma to find their symptoms worsening due to cannabis allergy and exposure to marijuana smoke.

• share
• favorite_border

New research shows children of caregivers with poor asthma knowledge were four times more likely to have a prolonged hospital stay. A “prolonged” stay was defined as more than two days.

• share
• favorite_border

New research found allergy shots provided significant benefits to the eczema symptoms suffered by a 48-year-old man.

• share
• favorite_border

New research examined what tools people who have food allergies use to prevent allergic reactions at restaurants.

• share
• favorite_border

What happens if you leave your epinephrine auto injector in your car in winter and it freezes? More than likely it will still work, according to new research.